CLINICAL TRIALS FUNDED
AWARD LIST.
Beginning during the fiscal year 2015-2016 Cancer League of Colorado’s Board of Directors approved funding of Investigator Initiated Clinical Trials. As of December 2023 the following Trials have been funded:
Amounts flagged (*) below are 50% funded by Cancer League of Colorado and 50% matched by MDC/RICHMOND AMERICAN HOMES FOUNDATION.
Nellowe Candelario, MD and Elizabeth Kessler, MD
2023
$100,000*
Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma with associated inferior vena cava tumor thrombus (NEOPAX)
David Westerly, PhD, Ryan Lanning, MD, PhD, Quentin Diot, PhD, MariahBrown, MD, Misha Miller, MD, Whitney High, MD, Karl Lewis, MD, Fred Sarazin, PhD, Jeramy Zimmerman, PhD
2021
$100.000
Superficial Treatment of Non-Melanoma Skin Cancer using Radioactive Film Therapy (RAFT)
Sana Karam, MD
2016
$50,000
A Dose Escalation Trial of Stereotatic Body Radiotherapy (SBRT) After Induction Chemotherapy for Locally Advanced Pancreatic Cancer
Paul Maroni, MD
2017
$50,000
A Phase 2 Study of Grape Seed Extract (GSE) Product I Asymptomatic Non-Metastatic Prostate Cancer Patients with Rising PSA
Clay Smith, MD and Dan Pollyea, MD
2017
$50,000
Phase I Trial of Arsenic Trioxide with Cyclophosphamide in Patients with Relapsed Refractory AML
S. Lindsey Davis, MD
2018
$50,000
Identifying biomarkers of immune-related toxicity in cancer Patients treated with immune checkpoint inhibitors; a pilot project
Elissa Kolva, PhD
2018
$50,000
Effect of Guided Imagery for Radiotherapy-Related Distress: A Randomized Controlled Trial for Patients with Head and Neck Cancer
Elizabeth Kessler, M.D.
2018
$70,000
Square wave Testosterone Therapy in castration resistant Prostate Cancer
Christine Fisher, MD,MPH and Jennifer Diamond MD
2019
$100,000
A randomized phase II Study of Anti-PD-1 and limited metastatic site radiation therapy versus anti-PD-1 alone for patients with microsatellite instability-high (MSI-H) and mismatch repair deficient (dMMR) metastatic solid tumors
Breelyn A. Wilky, MD
2019
$100,000
An Open label, Phase II Efficacy Trial of Doxorubicin and Olaratumab in Combination With Dual Checkpoint Blockade Using Agen1884 and Agen2034 for Advanced or Metastatic Soft Tissue Sarcomas
Jeffrey Olsen, MD and Alexis Leal, MD
2019
$50,000
Phase II Study of Induction FLOT Followed by Neoadjuvant Chemoradiation in Patients With Resectable Adenocarcinoma of the Esophagus Or Gastroesophageal Junction PRINCIPAL
Careye Cost, MD
2019
$50,000
A Phase I/1b Study of Losartan in Combination With Sunitimib in the Treatment of Pediatric and Adult Patients with Relapsed or Refractory Osteosarcoma
Ross Camidge, PhD and Rustain Morgan, MD
2019
$50,000
Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers with Actionable Driver Mutations
Jessica McDermott, MD
2019
$50,000
Study to Determine the Maximum Tolerated Dose and Recommended Phase 2 dose of ALA in Combination With Concurrent Chemoradiation in Head and Neck Cancer
Sana Karam, MD
2019
$100,000
A Phase 1b Study of sEpdBr-HAS in Combination with Cetuximab and Radiation Therapy in Patients with EGFR-Expressing Locally-Advanced Squamous Cell Carcinomas of the Head and Neck and Heavy Smoking Histories
Jose M. Pacheco, MD
2020
$50,000
A Pilot Study of Temozolomide in combination with Osimertinib or Lorlatinib in NSCLC patients with CS Progression on either Osimertinib or Lorlatinib